Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$324.55 ▲ +3.13
(+0.97%)
MKT CAP: $9.61B • VOL: 190.9K
52W L $184 52W H $383
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$273
MEDIAN
$364
MEAN
$370
HIGH
$441
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE KRYS TAPE
KRYS // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $392.71 | $373.23 | 2025-02-14 | $295.34 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $408.93 | $382.97 | 2025-02-06 | $305.08 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $369.99 | $357.01 | 2025-01-29 | $311.57 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $331.04 | — | 2025-01-17 | $318.06 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $285.60 | $308.32 | 2025-01-09 | $288.85 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $386.21 | $337.53 | 2024-12-18 | $282.36 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $314.81 | $327.80 | 2024-12-04 | $301.83 | -4.3% | 48% | C |